Filing Details
- Accession Number:
- 0001209191-17-048255
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-08-09 16:33:07
- Reporting Period:
- 2017-08-07
- Filing Date:
- 2017-08-09
- Accepted Time:
- 2017-08-09 16:33:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197032 | F Ian Smith | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Cfo & Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-08-07 | 4,250 | $77.31 | 120,138 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-08-07 | 400 | $154.09 | 119,738 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-08-07 | 2,600 | $155.29 | 117,138 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-08-07 | 1,250 | $156.02 | 115,888 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-08-07 | 4,250 | $0.00 | 4,250 | $77.31 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 8,500 | 2024-02-04 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 5,306 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $154.09 (range $153.67 to $154.50).
- Open market sales reported on this line occurred at a weighted average price of $155.29 (range $154.82 to $155.80).
- Open market sales reported on this line occurred at a weighted average price of $156.02 (range $155.87 to $156.26).
- The option vests in 16 quarterly installments from 2/5/2014.
Billionaire Hedge Funds
